UGO Rehabilitation Exoskeleton

Developed by RoboCT, the UGO Rehabilitation Exoskeleton represents the first Chinese-developed lower limb exoskeleton to receive NMPA registration specifically for neurological rehabilitation applications. The system has accumulated over 620,000 treatment sessions globally, serving patients across 40+ countries through hospital rehabilitation departments and home-use configurations.

Product Overview

UGO operates on the principle of neuroplasticity, providing repetitive, standardized gait training to help patients with lower limb motor dysfunction rebuild walking function. The device targets adults aged between 1.5m and 1.9m in height with a maximum weight capacity of 100kg. Both medical institution and household versions are available, with the household variant designed for continued therapy following initial clinical rehabilitation.

The system distinguishes itself through RoboCT’s proprietary multimodal biosignal fusion algorithms, integrating EMG, EEG, spinal cord signals, and motion data to achieve 98.7% intent recognition accuracy. Clinical studies demonstrate 53% improvement in gait training efficiency for stroke patients compared to conventional therapy.

Key Features

UGO is a lower limb rehabilitation exoskeleton by RoboCT, featuring 38-sensor motion tracking and four-joint brushless servo motors for neurological gait training.

• 38-Sensor Motion Tracking: The 38-sensor array enables precise detection of user movements and gait phases, allowing smooth adaptation to patient states throughout training sessions.

• Four-Joint Motor System: Brushless servo motors at hip and knee joints deliver reliable, controlled support while maintaining natural gait patterns.

• Electric Stand-Up Assistance: Automated transition from seated to standing position reduces physical burden on both patients and therapists.

• Cloud-Based Data Management: Rehabilitation cloud platform enables real-time monitoring, progress tracking, and remote rehabilitation guidance capabilities.

• Adjustable Sizing: Electric leg length adjustment accommodates users within the 1.5-1.9m height range without manual reconfiguration.

Technical Specifications

Designed for stroke and spinal cord injury rehabilitation, UGO supports users 1.5–1.9m tall at up to 100kg with cloud platform connectivity.

Clinical Applications

UGO addresses lower limb motor dysfunction resulting from central nervous system conditions. Primary indications include:

• Spinal cord injury (paraplegia, quadriplegia)
• Stroke (cerebrovascular accident)
• Hemiplegia
• Acquired brain injury
• Cerebral palsy (adult patients)
• Other central neuropathies

The system has demonstrated particular effectiveness in combined therapy protocols. Clinical collaboration with institutions including Xuanwu Hospital and Huashan Hospital has validated “spinal cord stimulation + exoskeleton” treatment approaches, with documented cases of patients achieving independent standing within 14 days and 5-meter independent walking within 28 days following intervention.

Regulatory Status

UGO holds the distinction of being the first Chinese neurological rehabilitation exoskeleton to achieve NMPA Class II registration, with an approved indication scope specifically covering central neuropathies including paraplegia and hemiplegia. The CE Mark certification obtained in late 2024 has enabled expansion into European, Middle Eastern, and Australian markets.

Frequently Asked Questions

What conditions is UGO designed to treat?

UGO is indicated for patients with lower limb motor dysfunction caused by central nervous system conditions, including spinal cord injury, stroke, hemiplegia, paraplegia, acquired brain injury, and other neurological diseases. The device helps rebuild walking function through repetitive gait training based on neuroplasticity principles.

Is UGO available for home use?

Yes, RoboCT offers both medical institution and household versions of UGO. The household variant enables patients to continue rehabilitation therapy at home following initial clinical treatment. The system is designed for operation by non-professionals after basic training.

How does UGO compare to other rehabilitation exoskeletons?

UGO differentiates through its multimodal biosignal fusion technology achieving 98.7% intent recognition accuracy, 100% domestic component production enabling competitive pricing, and full regulatory clearances (NMPA, CE, FDA). The system has accumulated over 620,000 patient treatment sessions across 40+ countries.